Submission guidelines
Instructions for Authors
SCOPE
The Journal of Clinical Immunology publishes high impact papers in the area of human immunology that explore the diagnosis, pathogenesis, prognosis, or treatment of human diseases. The Journal is particularly focused on primary immunodeficiencies and related diseases that include inborn errors of immunity, in the broad sense of the term, their underlying genotypes and their diverse phenotypes, including infection, malignancy, allergy, auto-inflammation, and autoimmunity. A wide range of studies in this area, ranging from genetic discovery, clinical description, immunologic assessment, diagnostic approach, prognosis evaluation, and treatment intervention defines the scope of the Journal. The Journal of Clinical Immunology publishes papers that include research using human subjects or human materials, as well as studies of relevant animal models that directly apply to human immunological disease(s). The Journal is particularly interested in the area of primary immunodeficiency and related diseases. Case reports are considered if they are truly original and are accompanied by a succinct review of the relevant medical literature and how the novel case study advances the field. Topical reviews are by invitation only.
ARTICLE TYPES
The Journal of Clinical Immunology publishes the following types of articles:
1. Letters to the Editor
2. Original Articles
3. CME Review Articles
4. “How I Manage” Articles
5. Commentary
Detailed instructions for each of these formats are provided below.
For each of these categories, papers that are being submitted to the Journal of Clinical Immunology must represent novel observations that have not have been published previously, nor be under consideration for publication elsewhere.
1. Letters to the Editor
The journal publishes Letters to the Editor, provided that they fit into one of the following categories: 1) Stand-alone original communications that bring out a focused but novel and important message on basic or clinical aspects of primary immune deficiencies and related diseases, including new findings related to diagnosis, pathogenesis, prognosis, or treatment; 2) Letters that relate to articles published in the Journal of Clinical Immunology but also contain significant new primary data and/or the inclusion of a figure and references to make important points, and 3) Clinical case reports where the patient’s description is novel and important, and adds new insights into disease pathogenesis, diagnosis, prognosis, or therapy.
Constructive comments on articles published in the Journal of Clinical Immunology received as a Letter to the Editor may be accompanied by a response from the author of the original article being commented on, which will be solicited by the Editors. Consideration for publication will be based on priority and interest to the readership as determined by an Editorial evaluation.
Letters to the Editor should begin with the salutation: “To the Editor”. They should have a clear and concise title (no more than 75 characters), include up to 5 authors, no abstract, and no more than 5 references. The total length of the Letter should not exceed a total of 2 printed pages, corresponding to approximately1,200 words and 1 figure or Table. However, additional Figures or tables could be posted as on line Supplemental Data.
Any involvement of medical writers/researchers, particularly those employed or supported by the pharmaceutical industry, in the writing of an article must be clearly defined and disclosed in the Authorship and/or the Acknowledgements section(s) before the references as appropriate. This type of involvement must also be disclosed to the Editor-in-Chief in the Cover Letter. For more information, see the “Disclosure of Potential Conflicts of Interest” tab farther below in Instructions for Authors.
Letters to the Editor are indexed by PubMed.
2. Original Articles
The journal publishes Regular Articles, which include: 1) original in-depth studies that bring out a novel and important message on basic or clinical aspects of primary immune deficiencies and related diseases, including new findings related to diagnosis, pathogenesis, prognosis, or treatment; 2) In rare circumstances, case reports where a patient’s description is not only novel and important, but also supported by in-depth genetic, immunological, and clinical data, thereby adding new insights into disease pathogenesis, diagnosis, prognosis, and therapy.
……
更多详情：
https://www.springer.com/journal/10875/submission-guidelines
